Liposarcoma: Molecular Targets and Therapeutic Implications

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2016 May 14

PMID 27173057

Citations 28

Authors

Kate Lynn J Bill

Lucia Casadei

Bethany C Prudner

Hans Iwenofu

Anne M Strohecker

Raphael E Pollock

Affiliations

Soon will be listed here.

Abstract

Liposarcoma (LPS) is the most common soft tissue sarcoma and accounts for approximately 20 % of all adult sarcomas. Current treatment modalities (surgery, chemotherapy, and radiotherapy) all have limitations; therefore, molecularly driven studies are needed to improve the identification and increased understanding of genetic and epigenetic deregulations in LPS if we are to successfully target specific tumorigenic drivers. It can be anticipated that such biology-driven therapeutics will improve treatments by selectively deleting cancer cells while sparing normal tissues. This review will focus on several therapeutically actionable molecular markers identified in well-differentiated LPS and dedifferentiated LPS, highlighting their potential clinical applicability.

Citing Articles

Clinico-Radiological-Pathological Correlation in a Rapidly Evolving Well-Differentiated Orbital Liposarcoma: A Case Report.

Iwasaki R, Kitaguchi Y, Hayashi S, Morimoto T, Nishida K Cureus. 2025; 17(1):e77674.

PMID: 39974236 PMC: 11835626. DOI: 10.7759/cureus.77674.

Primary dedifferentiated liposarcoma of the gallbladder: a case report and literature review.

Wang L, Lin T, Hai Y, Yu K, Bu F, Lu J Front Surg. 2024; 11:1452144.

PMID: 39606156 PMC: 11599167. DOI: 10.3389/fsurg.2024.1452144.

Liposarcoma: A Journey into a Rare Tumor's Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies.

Jonczak E, Grossman J, Alessandrino F, Seldon Taswell C, Velez-Torres J, Trent J Cancers (Basel). 2024; 16(22).

PMID: 39594813 PMC: 11592651. DOI: 10.3390/cancers16223858.

Pleomorphic Liposarcoma Unraveled: Investigating Histopathological and Immunohistochemical Markers for Tailored Diagnosis and Therapeutic Innovations.

Ciongariu A, Tapoi D, Dumitru A, Bejenariu A, Marin A, Costache M Medicina (Kaunas). 2024; 60(6).

PMID: 38929567 PMC: 11205576. DOI: 10.3390/medicina60060950.

Explainable machine learning predicts survival of retroperitoneal liposarcoma: A study based on the SEER database and external validation in China.

Wang M, Li Z, Zeng S, Wang Z, Ying Y, He W Cancer Med. 2024; 13(11):e7324.

PMID: 38847519 PMC: 11157677. DOI: 10.1002/cam4.7324.

References

Henricks W, Chu Y, Goldblum J, Weiss S . Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997; 21(3):271-81. DOI: 10.1097/00000478-199703000-00002. View

Panotopoulos J, Posch F, Alici B, Funovics P, Stihsen C, Amann G . Hemoglobin, alkalic phosphatase, and C-reactive protein predict the outcome in patients with liposarcoma. J Orthop Res. 2015; 33(5):765-70. DOI: 10.1002/jor.22827. View

Ferracini R, Olivero M, Di Renzo M, Martano M, De Giovanni C, Nanni P . Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene. 1996; 12(8):1697-705. View

Mandahl N, Hoglund M, Mertens F, Rydholm A, Willen H, Brosjo O . Cytogenetic aberrations in 188 benign and borderline adipose tissue tumors. Genes Chromosomes Cancer. 1994; 9(3):207-15. DOI: 10.1002/gcc.2870090309. View

Dalal K, Kattan M, Antonescu C, Brennan M, Singer S . Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006; 244(3):381-91. PMC: 1856537. DOI: 10.1097/01.sla.0000234795.98607.00. View

Ghadimi M, Al-Zaid T, Madewell J, Peng T, Colombo C, Hoffman A . Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Ann Surg Oncol. 2011; 18(13):3762-70. DOI: 10.1245/s10434-011-1794-0. View

Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B . Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol. 1998; 185(2):188-90. DOI: 10.1002/(SICI)1096-9896(199806)185:2<188::AID-PATH53>3.0.CO;2-2. View

Evans H . Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979; 3(6):507-23. DOI: 10.1097/00000478-197912000-00004. View

Ma R, Jiang T, Kang X . Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012; 31:38. PMC: 3431991. DOI: 10.1186/1756-9966-31-38. View

10.

Zhang Y, Sicinska E, Czaplinski J, Remillard S, Moss S, Wang Y . Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014; 13(9):2184-93. DOI: 10.1158/1535-7163.MCT-14-0387. View

11.

Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R . An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2010; 91(3):392-403. PMC: 3058694. DOI: 10.1038/labinvest.2010.185. View

12.

Weng Y, Chen Y, Chen J, Liu Y, Bao T . Identification of serum microRNAs in genome-wide serum microRNA expression profiles as novel noninvasive biomarkers for malignant peripheral nerve sheath tumor diagnosis. Med Oncol. 2013; 30(2):531. DOI: 10.1007/s12032-013-0531-x. View

13.

Matushansky I, Hernando E, Socci N, Matos T, Mills J, Edgar M . A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol. 2008; 172(4):1069-80. PMC: 2276417. DOI: 10.2353/ajpath.2008.070284. View

14.

Que W, Chen J . Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep. 2011; 4(2):343-9. DOI: 10.3892/mmr.2011.426. View

15.

Thway K, Jones R, Noujaim J, Zaidi S, Miah A, Fisher C . Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2015; 23(1):30-40. DOI: 10.1097/PAP.0000000000000101. View

16.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

17.

Redis R, Calin S, Yang Y, You M, Calin G . Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012; 136(2):169-74. PMC: 3855335. DOI: 10.1016/j.pharmthera.2012.08.003. View

18.

Lahat G, Anaya D, Wang X, Tuvin D, Lev D, Pollock R . Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol. 2008; 15(6):1585-93. DOI: 10.1245/s10434-007-9805-x. View

19.

Ballman K . Biomarker: Predictive or Prognostic?. J Clin Oncol. 2015; 33(33):3968-71. DOI: 10.1200/JCO.2015.63.3651. View

20.

Sandberg A . Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet. 2004; 155(1):1-24. DOI: 10.1016/j.cancergencyto.2004.08.005. View